JP2006506371A - ラクトバチルス・リューテリ(Lactobacillusreuteri)株を用いる哺乳類における免疫機能の改善方法 - Google Patents
ラクトバチルス・リューテリ(Lactobacillusreuteri)株を用いる哺乳類における免疫機能の改善方法 Download PDFInfo
- Publication number
- JP2006506371A JP2006506371A JP2004545114A JP2004545114A JP2006506371A JP 2006506371 A JP2006506371 A JP 2006506371A JP 2004545114 A JP2004545114 A JP 2004545114A JP 2004545114 A JP2004545114 A JP 2004545114A JP 2006506371 A JP2006506371 A JP 2006506371A
- Authority
- JP
- Japan
- Prior art keywords
- strain
- reuteri
- cells
- day
- subjects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 21
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims abstract description 14
- 230000036737 immune function Effects 0.000 title claims abstract description 11
- 241000124008 Mammalia Species 0.000 title claims abstract description 9
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 8
- 230000024033 toxin binding Effects 0.000 claims abstract description 6
- 239000012228 culture supernatant Substances 0.000 claims description 21
- 239000000047 product Substances 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 231100000699 Bacterial toxin Toxicity 0.000 claims 1
- 239000000688 bacterial toxin Substances 0.000 claims 1
- 230000006041 cell recruitment Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 63
- 108010017898 Shiga Toxins Proteins 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 34
- 239000000243 solution Substances 0.000 description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 238000001574 biopsy Methods 0.000 description 14
- 239000003053 toxin Substances 0.000 description 14
- 231100000765 toxin Toxicity 0.000 description 14
- 108700012359 toxins Proteins 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 9
- 230000000120 cytopathologic effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 210000001198 duodenum Anatomy 0.000 description 8
- 230000037406 food intake Effects 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 210000003501 vero cell Anatomy 0.000 description 8
- 241000186660 Lactobacillus Species 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 4
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 102100025136 Macrosialin Human genes 0.000 description 4
- 238000002575 gastroscopy Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000589989 Helicobacter Species 0.000 description 3
- 244000199866 Lactobacillus casei Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940071604 biogaia Drugs 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 229940118526 interleukin-9 Drugs 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- UJTTUOLQLCQZEA-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(4-hydroxybutyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCCCO)C3=CC=CC=C3C2=C1 UJTTUOLQLCQZEA-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001135786 Lactobacillus cerevisiae Species 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 229940111205 diastase Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000007455 ileostomy Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
3種の乳酸菌、L.リューテリATCC55730、L.ブルガリクス(L.bulgaricus)、菌株LB12(CHR,Horsholm,Denmark)、およびL.カゼイ(L.casei)、菌株01(CHR,Horsholm,Denmark)がこの実験において用いられた。L.リューテリは、MRSブロス(20mMグルコースを補足)に接種した後、37℃で24〜48時間屈気性(aerotropic)固定(fixing)条件下でインキュベートされた。ある場合には、この初期インキュベーションの後、2,500rpmで30分間の遠心、リン酸緩衝化生理食塩水で2回の洗浄による培地成分の除去、250mMグリセロール溶液への懸濁、続いて屈気性固定条件下37℃で6時間のインキュベーションを実施した。L.ブルガリクスおよびL.カゼイは屈気的固定条件下37℃で24〜48時間MRSプラス20mMグルコース(グリセロール不含)においてインキュベートされた。各供試乳酸菌は、2g/30ml(乾燥重量)に調節し、インキュベーション後2,500rpmで30分間遠心し、上澄液を回収し、ベロ(vero)細胞(下記参照)を接種するためにNaOHによりpH7.0に調節し、そして2.0μmフィルターを通して濾過した後使用された。グリセロール溶液およびpH7.0に調節したMRSブロスは、2.0μmフィルターを通して濾過後、対照として使用された。
TSB、MRSブロスおよびグリセロール溶液がベロ細胞に添加された場合、細胞変性効果は見られなかった。さらに、両VTおよびMRSブロス/グリセロール溶液がベロ細胞に添加された場合、CPEがベロ細胞において観察され、このことは、培養液それ自体はVTに対する中和能力を欠くことを証明している。
この試験では、被験者は2個の咀しゃく錠剤を1日当たり2回与えられたが、各錠剤はL.リューテリ(SD2112:ATCC55730)の1x108CFU(コロニー形成単位)を含有し、4x108CFU L.リューテリの総1日用量になる。錠剤に使用されたすべての他の添加物は周知のものであり、そして国際薬局方に従った。研究は2部:上部胃腸管の探索を含む胃鏡検査セッション、および末端小腸の探索を含む回腸鏡検査セッションにおいて実施された(以下に詳述)。除外基準は、研究2週前および研究中に摂取される抗生物質;研究3週前および研究中に摂取される共生生物、胃腸関連の薬物による進行中の処置および規則的な処置を必要とする重い臓器疾患(例えば、がん)であった。患者の処置に関するプロトコールは、デンマーク医療委員会(Danish Ethical Committee)によって承認され、そしてヘルシンキの布告(declaration of Helsinki)にしたがった。研究はデンマークにおいて実施された。
便サンプルはL.リューテリの摂取前(0日目)および研究の終了時(28日目)に各被験者から収集された。回腸鏡検査の被験者の便(以下に説明する)は小口から採取された。胃鏡検査セッションからの7ボランティアおよび回腸鏡検査セッションからの4ボランティアは42日目(L.リューテリ摂取の停止14日後)に便サンプルを収集した。サンプル(少なくとも5g)が無菌容器中に収集され、そして直ちに冷蔵庫に入れた。24時間内に、0.1%ペプトン水20ml(1:5,wt/vol)が添加された。サンプルはホモジナイズされ、そして一定分量が寒冷容器中に分配された後直ちに−70℃で凍結された。そのサンプルが総ラクトバチルス菌とL.リューテリの分析のためにBiogaia AB研究所に向けてドライアイスで凍結されて発送された。そこで、サンプルは解凍され、希釈され、そしてL.リューテリについてはバンコマイシン(50mg/l)を含有するMRS−3寒天、そして総ラクトバチルス菌数についてはLBS寒天プレート(KEBOLAB AB,Lund,Sweden)上に塗布された。MRS−3は2%酢酸ナトリウム(wt/vol)を含有する改変MRS−3寒天(KEBOLAB AB,Lund,Sweden)である。LBS寒天は1L当たり1.32mlの氷酢酸を添加することによって販売者により推奨されたように調製された。寒天プレートは37℃で48時間嫌気ジャーにおいてBBL Gasパックを用いて嫌気的にインキュベートされた。研究において選ばれた分離株からのDNAはBacterial Barcodes repPROTM DNA Fingerprintingキット(Bacterial BarCodes,Inc.,Houston,TX)を用いてPCRによって分析され、そしてフィンガープリントはBionumericsソフトウェア(Applied Maths BVBA,Sint−Martens−Latem,Belgium)を用いて解析された。
いずれかの局部的免疫応答を評価するために、B−リンパ球、T−リンパ球およびマクロファージの量における変化が測定された。基礎の生検材料および28日目の生検材料がホルマリン固定され、そしてパラフィン中に包埋された。続いて、4μmの切片が切り取られ、そして標準的技術(Hematoxylin−eosin,van Gieson,PeriodicAcidSciff−AlcainおよびPeriodicAcidSciff−diastase)を用いて組織化学的および免疫組織化学的に染色された。CD20(B−リンパ球)、CD3,CD4+,CD8(T−リンパ球)、CD68(組織球)、ヘリコバクターおよびKi−67(増殖マーカー)に対する1次抗体は、DAKO,Glostrup,Denmarkから得られた。免疫組織化学的染色は、均一な染色を得るためにDAKO TechMateTM500イムノステイナーにおいて実施された。
血液サンプルは0日目および28日目に採取され、そしてヘモグロビン、ヘマトクリット、血小板、白血球、C−反応性タンパク質、カリウム、ナトリウム、クレアチン、b−尿素、p−グルコース、コレステロール、HDL(高密度リポタンパク質)、LDL(低密度リポタンパク質)、VLDL(超低密度リポタンパク質)、トリグリセリド、総ビリルビン、尿酸塩、ALAT、アルカリ性ホスファターゼおよび乳酸塩について分析された。
DNAのフィンガープリント分析が本研究から選択されたL.リューテリ分離株において実施された。かくして、28日間L.リューテリを消費した3人の被験者からの便分離株が採取され、そして十二指腸生検材料からの1分離株および回腸生検材料からの1分離株がともに、L.リューテリ投与前0日目に採取された。全分離株は互いに98%の遺伝的類似性を有することが見い出された。これらの分離株のすべては、錠剤に組み入れられた菌株、SD2112に対する97%の類似性を示した。
この実施例では、標準ヨーグルトに添加するために、毒素の中和およびCD4+細胞の動員について前記方法を用いてL.リューテリSD2112,ATCC55730が選ばれた。L.リューテリ菌株は、酪農産業においてラクトバチルスを増殖させるための標準的方法を用いて増殖され、そして凍結乾燥された。次いで、この培養物が10E+7CFU/gヨーグルトのレベルで慣用のヨーグルト培養物を用いて予め発酵させた牛乳に添加され、そしてヨーグルトはヒトの免疫機能を改善する手段としてヒトによって使用される。
VT+G: VT+250mMグリセロール溶液
VT+LRS: VT+250mMグリセロール溶液においてインキュベートしたL. リューテリの培養上澄液
Claims (9)
- 哺乳類における免疫機能を改善する組成物の製造のための、
a.良好な毒素の結合と中和効果を示し;そして
b.良好なCD4+細胞の動員を示す
ラクトバチルス・リューテリ(Lactobachillus reuteri)株の使用。 - 少なくとも請求項1に記載する特徴を有する菌株を含んでなる製品。
- 選ばれた菌株の細胞を含有する食料として調製される、請求項2の製品。
- 選ばれた菌株の細胞を含有する錠剤として製剤化される、請求項2の製品。
- 選ばれた菌株の細胞を含有する食物サプリメントとして製剤化される、請求項2の製品。
- 選ばれた菌株の細胞を含有する菓子として調製される、請求項2の製品。
- 選ばれた菌株の細胞を含有する薬物として製剤化される、請求項2の製品。
- 細菌毒素を中和するための、L.リューテリATCC55730の培養上澄液の使用。
- a.良好な毒素の結合と中和効果を示し;そして
b.良好なCD4+細胞の動員を示す
菌株を使用することを含む、そのような菌株の細胞を含有する製品においてラクトバチルス・リューテリ(Lactobacillus reuteri)株を用いる哺乳類における免疫機能を改善する方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/SE2002/001903 WO2004034808A1 (en) | 2002-10-18 | 2002-10-18 | Method of improving immune function in mammals using lactobacillus reuteri strains |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010152168A Division JP2010280664A (ja) | 2010-07-02 | 2010-07-02 | ラクトバチルス・リューテリ(Lactobacillusreuteri)株を用いる哺乳類における免疫機能の改善方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006506371A true JP2006506371A (ja) | 2006-02-23 |
Family
ID=32105771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004545114A Withdrawn JP2006506371A (ja) | 2002-10-18 | 2002-10-18 | ラクトバチルス・リューテリ(Lactobacillusreuteri)株を用いる哺乳類における免疫機能の改善方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20060002907A1 (ja) |
EP (1) | EP1567018B1 (ja) |
JP (1) | JP2006506371A (ja) |
CN (1) | CN100348119C (ja) |
AT (1) | ATE434940T1 (ja) |
AU (1) | AU2002347697B2 (ja) |
BR (1) | BR0215884A (ja) |
DE (1) | DE60232827D1 (ja) |
DK (1) | DK1567018T3 (ja) |
ES (1) | ES2329020T3 (ja) |
HK (1) | HK1079661A1 (ja) |
MX (1) | MXPA05003743A (ja) |
WO (1) | WO2004034808A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010519900A (ja) * | 2007-03-02 | 2010-06-10 | バイオガイア・エイビー | ペット動物の飼料リシン吸収を改善するための乳酸菌の使用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7955834B2 (en) * | 2004-06-03 | 2011-06-07 | Biogaia Ab | Method for improved breast milk feeding to reduce the risk of allergy |
WO2006064449A1 (en) * | 2004-12-15 | 2006-06-22 | Van Der Westhuizen Cornelis Fl | Detoxifying and immunity-booster composition |
US20060251634A1 (en) * | 2005-05-06 | 2006-11-09 | Ho-Jin Kang | Method of improving immune function in mammals using lactobacillus strains with certain lipids |
US7374924B2 (en) * | 2006-06-05 | 2008-05-20 | Biogaia Ab | Use of selected lactic acid bacteria for reducing infantile colic |
FI121952B (fi) | 2009-05-06 | 2011-06-30 | Oriola Oy | Menetelmä pisaroina annosteltavan terveystuotteen valmistamiseksi |
US20110293710A1 (en) * | 2010-02-02 | 2011-12-01 | Delphine Saulnier | Immunomodulatory properties of lactobacillus strains |
RU2721565C2 (ru) * | 2014-05-05 | 2020-05-20 | Джованни МОНЬЯ | Терапевтическое средство для применения в лечении опухолей, синдрома приобретенного иммунодефицита и лейкозов путем двойной иммунной биостимуляции |
RU2713414C2 (ru) | 2014-05-05 | 2020-02-05 | Джованни МОНЬЯ | Композиция для применения в лечении или предупреждении вирусных или бактериальных инфекций у субъекта, проходящего противоопухолевую химиотерапию, лечение лейкоза или лечение СПИД, содержащая l.reuteri ler03 и/или l.salivarius ls06 |
AU2020352646A1 (en) * | 2019-09-26 | 2022-03-24 | Precisionbiotics Group Limited | Lactobacillus reuteri |
CN113073066B (zh) * | 2021-04-16 | 2022-01-04 | 段云峰 | 罗伊氏乳杆菌及其应用、组合物、药物和食品 |
CN113881597B (zh) * | 2021-10-15 | 2023-04-28 | 江南大学 | 一株能够提高吲哚丙烯酸以调节特异性IgE的罗伊氏乳杆菌 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0648124A4 (en) * | 1992-06-25 | 1996-05-08 | Biogaia Biolog Ab | METHOD FOR STIMULATING THE IMMUNE SYSTEM. |
DE69627994D1 (de) * | 1995-12-21 | 2003-06-12 | Biogaia Ab Stockholm | Verwendung von lactobacillus reuteri zur hemmung der kryptosporidiosis in säugetieren |
DE69707413T3 (de) * | 1997-01-09 | 2009-07-02 | Société des Produits Nestlé S.A. | Probiotik enthaltendes Getreideprodukt |
WO1999017788A1 (en) * | 1997-10-06 | 1999-04-15 | Abbott Laboratories | Composition of treatment of candidiasis |
US6461607B1 (en) * | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
US7105336B2 (en) * | 2002-10-07 | 2006-09-12 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter |
-
2002
- 2002-10-18 DK DK02783892T patent/DK1567018T3/da active
- 2002-10-18 BR BR0215884-1A patent/BR0215884A/pt not_active Application Discontinuation
- 2002-10-18 EP EP02783892A patent/EP1567018B1/en not_active Expired - Lifetime
- 2002-10-18 AU AU2002347697A patent/AU2002347697B2/en not_active Ceased
- 2002-10-18 AT AT02783892T patent/ATE434940T1/de active
- 2002-10-18 JP JP2004545114A patent/JP2006506371A/ja not_active Withdrawn
- 2002-10-18 CN CNB028296958A patent/CN100348119C/zh not_active Expired - Fee Related
- 2002-10-18 US US10/531,651 patent/US20060002907A1/en not_active Abandoned
- 2002-10-18 ES ES02783892T patent/ES2329020T3/es not_active Expired - Lifetime
- 2002-10-18 DE DE60232827T patent/DE60232827D1/de not_active Expired - Lifetime
- 2002-10-18 WO PCT/SE2002/001903 patent/WO2004034808A1/en active Application Filing
- 2002-10-18 MX MXPA05003743A patent/MXPA05003743A/es active IP Right Grant
-
2005
- 2005-12-23 HK HK05111951A patent/HK1079661A1/xx not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010519900A (ja) * | 2007-03-02 | 2010-06-10 | バイオガイア・エイビー | ペット動物の飼料リシン吸収を改善するための乳酸菌の使用 |
Also Published As
Publication number | Publication date |
---|---|
WO2004034808A1 (en) | 2004-04-29 |
AU2002347697A1 (en) | 2004-05-04 |
DE60232827D1 (de) | 2009-08-13 |
ES2329020T3 (es) | 2009-11-20 |
CN1668211A (zh) | 2005-09-14 |
AU2002347697B2 (en) | 2008-03-20 |
DK1567018T3 (da) | 2009-09-14 |
CN100348119C (zh) | 2007-11-14 |
HK1079661A1 (en) | 2006-04-13 |
BR0215884A (pt) | 2005-12-20 |
US20060002907A1 (en) | 2006-01-05 |
EP1567018A1 (en) | 2005-08-31 |
MXPA05003743A (es) | 2005-06-17 |
ATE434940T1 (de) | 2009-07-15 |
EP1567018B1 (en) | 2009-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wostmann | Germfree and gnotobiotic animal models: background and applications | |
JP4706016B2 (ja) | 炎症性疾患治療におけるビフィドバクテリウム(Bifidobacterium) | |
US9314041B2 (en) | Immune function modulating agents | |
EP1758604B1 (en) | Method for improved breast milk feeding to reduce the risk of allergy | |
Sun et al. | Effects of Enterococcus faecium (SF68) on immune function in mice | |
EP2162143A1 (en) | Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis | |
JP6985342B2 (ja) | ビフィドバクテリウム ラクティス gkk2、それを含む組成物、およびアレルギー性喘息改善のためのその使用 | |
Yu et al. | Lactobacillus cells in the rabbit digestive tract and the factors affecting their distribution | |
JP2006506371A (ja) | ラクトバチルス・リューテリ(Lactobacillusreuteri)株を用いる哺乳類における免疫機能の改善方法 | |
DK2707476T3 (en) | Lactobacillus fermentum CECTA 7472 strain with probiotic properties | |
Conway et al. | Strategies for the isolation and characterisation of functional probiotics | |
JP2010280664A (ja) | ラクトバチルス・リューテリ(Lactobacillusreuteri)株を用いる哺乳類における免疫機能の改善方法 | |
KR100887819B1 (ko) | 락토바실러스 루테리 균주를 이용하여 포유동물에서 면역 기능을 향상시키는 방법 | |
KR100887822B1 (ko) | 락토바실러스 루테리 균주를 이용하여 포유동물에서 면역기능을 향상시키는 방법 | |
Rinkinen | Methods for assessing the adhesion of probiotic and canine gut-derived lactic acid producing bacteria to the canine intestinal mucosa in vitro and measuring mucosal secretory IgA | |
ZA200502601B (en) | Method of improving immune function in mammals using lactobacillus reuteri strains | |
Thoreux et al. | Functional foods, mucosal immunity and aging: effect of probiotics on intestinal immunity in young and old rats | |
Mandal | Study of Lactobacillus Isolates from Human Sources with regard to Their Beneficial Physiological Attributes | |
McCoy | Effects of feeding Lactobacillus reuteri X-18 on blood chemistry and immune parameters in beagle (Canis familiaris) puppies | |
Wong | Effect of lactic acid bacteria and bifidobacteria on interleukin-6 and interleukin-8 production by Caco-2 cells | |
Block | Modulation of Escherichia coli O157: H7 mediated production of proinflammatory mediators by two species of Lactobacilli in two conditionally immortal colon epithelial cell lines | |
Qiu | DFM/Probiotic Effects on Gastrointestinal Tract Development and Immune Function in Broiler Chicken |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080908 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090526 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090826 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091120 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100702 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100707 |